News
12-09-2012, 09:30 PM
Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.
More... (http://www.news-medical.net/news/20121209/Celldex-announces-final-results-from-CDX-011-Phase-2b-study-on-GPNMB-expressing-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20121209/Celldex-announces-final-results-from-CDX-011-Phase-2b-study-on-GPNMB-expressing-breast-cancer.aspx)